L’amphotéricine B liposomale en prophylaxie secondaire chez les patients VIH+ atteints de leishmaniose viscérale : à propos de cinq cas-Reference-Cited by-同舟云学术

L’amphotéricine B liposomale en prophylaxie secondaire chez les patients VIH+ atteints de leishmaniose viscérale : à propos de cinq cas

Published:2004-03 Issue:2 Volume:52 Page:66-75
ISSN:0369-8114
Container-title:Pathologie Biologie
language:fr
Short-container-title:Pathologie Biologie

Author:

Montana M,Chochoi N,Monges P,Ravaux I,Faraut F,Gensollen S,Bongrand M.C,Timon-David P,Gallais H

Publisher

Elsevier BV

Subject

General Medicine

Reference40 articles.

1. Rapport OMS no 116 révisé Mai 2000 available from: URL: http://www.who.int/inf-fs/fr/am116.htlm.

2. Basset D, Pratlong F, Ravel C, Puechberty J, Dereure J, Dedet JP : « Les leishmanioses déclarées en France en 1999 », available from: URL: http://www.invs.sante.fr/beh/2001/05/arde1041.htm.

3. « Traitement de la leishmaniose viscérale : modalités récentes »;Gangneux;La presse médicale,1999

4. “Treatment of mediterranean visceral leishmaniasis”;Gradoni;Bulletin of World health organization,1995

5. “Clinicoepidemiologic characteristics, pronostic factors, and survival analysis of patients coinfected with HIV and Leishmania in an area of Madrid”;Lopez-Velez;Am J Trop Med Hyg,1998

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanomedicines - Tiny particles and big challenges;Advanced Drug Delivery Reviews;2019-11

2. Current and emerging medications for the treatment of leishmaniasis;Expert Opinion on Pharmacotherapy;2019-05-07

3. Recent developments and future prospects in the treatment of visceral leishmaniasis;Therapeutic Advances in Infectious Disease;2016-06

4. A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance;Kala Azar in South Asia;2016

5. An update on pharmacotherapy for leishmaniasis;Expert Opinion on Pharmacotherapy;2014-10-25